Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by aldo451on Jan 02, 2020 1:43pm
79 Views
Post# 30511771

RE:RE:u lie again, riplazym partnership promised h1 2020

RE:RE:u lie again, riplazym partnership promised h1 2020Well it appears you can't read either, it clearly says "expected"

Slide 3

Expected Ryplazim™ global marketing partnership


Slide 6

2019

Expected commercial partnership for Ryplazim™


biotech1973 wrote:
OMG you cant read it . It clearly says 2019 - Not Done. H1 is for commercialzation


<< Previous
Bullboard Posts
Next >>